Louis Bourhoven

Louis Bourhoven

Auto-generated profile, based on publicly available information

Louis Bourhoven

Neuroscience Unit, University Hospital Center of Quebec–Laval University

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
RTReza Taghipour-Mirakmahaleh
Reza Taghipour-Mirakmahaleh
FMFrançoise Morin
Françoise Morin
YZYu Zhang
Yu Zhang
LBLouis Bourhoven
Louis Bourhoven
LBLouis-Charles Béland
Louis-Charles Béland
LVLuc Vallières
Luc Vallières
Autoantibodies contribute to many autoimmune diseases, yet there is no approved therapy to neutralize them selectively. A popular mouse model, experimental autoimmune encephalomyelitis (EAE), could serve to develop such a therapy, provided we can better understand the nature and importance of the autoantibodies involved. Here, we report the finding of autoantibody-secreting extrafollicular plasmablasts in EAE induced with specific myelin oligodendrocyte glycoprotein (MOG) antigens. Single-cell RNA sequencing reveals that these cells produce nonaffinity-matured IgG antibodies. These include pathogenic antibodies competing for shared binding space on MOG’s extracellular domain. Interestingly, the synthetic anti-MOG antibody 8-18C5 can prevent the binding of pathogenic antibodies from either EAE mice or people with MOG antibody disease. Moreover, an 8-18C5 variant carrying the NNAS mutation, which inactivates its effector functions, can reduce EAE severity and promote functional recovery. In brief, this study provides not only a comprehensive characterization of the humoral response in EAE models but also a proof of concept for a therapy to antagonize pathogenic anti-MOG antibodies.